Literature DB >> 2757544

Clinical risk factors for proliferative vitreoretinopathy.

M Cowley1, B P Conway, P A Campochiaro, D Kaiser, H Gaskin.   

Abstract

We reviewed the records of all patients with rhegmatogenous retinal detachments examined and treated by a single surgeon (B.P.C.) at the University of Virginia, Charlottesville, between 1978 and 1984. Of the 607 eyes that satisfied the selection criteria, a preliminary chart review of outcomes found that 65 (10.7%) had proliferative vitreoretinopathy and 34 had macular puckers. From the remaining 508 eyes, 325 controls were randomly selected to match each case from within a time window. Thirty-six (55.4%) of the 65 patients with proliferative vitreoretinopathy had had unequivocal reattachment after a single procedure before the onset of proliferative vitreoretinopathy, and the only clearly identified technical difficulty that was significantly more common in the patients with proliferative vitreoretinopathy was the inability to identify a retinal break. Several other features of the rhegmatogenous retinal detachments that correlated with the development of postoperative proliferative vitreoretinopathy were identified, and stepwise discriminant analysis was used to ascertain which of these were more important. The strongest predictor was use of vitrectomy in management of the detachment. Following this in order of importance were the presence of preoperative proliferative vitreoretinopathy, preoperative choroidal detachment, and the amount of cryopexy required. Vitrectomy remained a strong predictor even when considered after adjustment for all other characteristics. These data suggest that proliferative vitreoretinopathy is not simply an iatrogenic disease, but it is more likely to occur in association with certain detachment features that either by themselves or through their management require prolongation of the retinal wound healing process.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2757544     DOI: 10.1001/archopht.1989.01070020213027

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  45 in total

1.  Tailored vitrectomy and laser photocoagulation without scleral buckling for all primary rhegmatogenous retinal detachments.

Authors:  K Johansson; M Malmsjö; F Ghosh
Journal:  Br J Ophthalmol       Date:  2006-07-12       Impact factor: 4.638

2.  Buckle, no cryo: scleral buckle with no cryotherapy for retinal detachment secondary to commotio retinae.

Authors:  M A Majid; H M Hussain; R J Haynes; A D Dick
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

3.  Early vitrectomy for fundus-obscuring dense vitreous haemorrhage from presumptive retinal tears.

Authors:  Narendra Dhingra; Ian Pearce; David Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02       Impact factor: 3.117

Review 4.  THE PATHOGENY OF PROLIFERATIVE VITREORETINOPATHY.

Authors:  Danielescu Ciprian
Journal:  Rom J Ophthalmol       Date:  2015 Apr-Jun

5.  Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes.

Authors:  Y S Chen; S F Hackett; C L Schoenfeld; M A Vinores; S A Vinores; P A Campochiaro
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

6.  Connective tissue growth factor as a mediator of intraocular fibrosis.

Authors:  Shikun He; Youxin Chen; Rima Khankan; Ernesto Barron; Richard Burton; Danhong Zhu; Stephen J Ryan; Noelynn Oliver; David R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-30       Impact factor: 4.799

7.  The chemoattractant activity of the vitreous to human scleral fibroblasts following retinal detachment and proliferative vitreoretinopathy.

Authors:  N Wilson-Holt; P Khaw; F Savage; I Grierson
Journal:  Br J Ophthalmol       Date:  1992-03       Impact factor: 4.638

Review 8.  Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy.

Authors:  Hetian Lei; Marc-Andre Rheaume; Andrius Kazlauskas
Journal:  Exp Eye Res       Date:  2009-11-25       Impact factor: 3.467

9.  An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy.

Authors:  J A Cardillo; M E Farah; J Mitre; P H Morales; R A Costa; L A S Melo; B Kuppermann; R Jorge; P Ashton
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

10.  Primary vitrectomy for rhegmatogenous retinal detachment.

Authors:  K N Hakin; M J Lavin; P K Leaver
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-06       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.